Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleksandra Franovic

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Oncology|April 26, 2019
Detection of <i>ERBB2</i> (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient CohortJeeyun Lee, Aleksandra Franovic, Yukimasa Shiotsu, et al.
Nature|June 9, 2012
An oxygen-regulated switch in the protein synthesis machineryJames Uniacke, Chet E Holterman, Gabriel Lachance, et al.
The Journal of Biological Chemistry|August 29, 2003
Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cellsLakshman Gunaratnam, Melissa Morley, Aleksandra Franovic, et al.
Nature Communications|September 4, 2015
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2Sunil J Advani, Maria Fernanda Camargo, Laetitia Seguin, et al.
Nature Medicine|November 15, 2011
A MEK-independent role for CRAF in mitosis and tumor progressionAinhoa Mielgo, Laetitia Seguin, Miller Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain MutationsEranga R Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
Nature Communications|November 26, 2016
MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironmentRaeAnna Wilson, Cristina Espinosa-Diez, Nathan Kanner, et al.
Journal of Medicinal Chemistry|January 24, 2024
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJohn S Tyhonas, Lee D Arnold, Jason M Cox, et al.
Nature Cell Biology|April 22, 2014
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibitionLaetitia Seguin, Shumei Kato, Aleksandra Franovic, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|April 26, 2019
Detection of <i>ERBB2</i> (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient CohortJeeyun Lee, Aleksandra Franovic, Yukimasa Shiotsu, et al.
Nature|June 9, 2012
An oxygen-regulated switch in the protein synthesis machineryJames Uniacke, Chet E Holterman, Gabriel Lachance, et al.
The Journal of Biological Chemistry|August 29, 2003
Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cellsLakshman Gunaratnam, Melissa Morley, Aleksandra Franovic, et al.
Nature Communications|September 4, 2015
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2Sunil J Advani, Maria Fernanda Camargo, Laetitia Seguin, et al.
Nature Medicine|November 15, 2011
A MEK-independent role for CRAF in mitosis and tumor progressionAinhoa Mielgo, Laetitia Seguin, Miller Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain MutationsEranga R Balasooriya, Qibiao Wu, Haley Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2016
Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or MutationsGang G Li, Romel Somwar, James Joseph, et al.
Nature Communications|November 26, 2016
MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironmentRaeAnna Wilson, Cristina Espinosa-Diez, Nathan Kanner, et al.
Journal of Medicinal Chemistry|January 24, 2024
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene AlterationsJohn S Tyhonas, Lee D Arnold, Jason M Cox, et al.
Nature Cell Biology|April 22, 2014
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibitionLaetitia Seguin, Shumei Kato, Aleksandra Franovic, et al.
Pageof 3